How inclusive are cell lines in preclinical engineered cancer models?
How inclusive are cell lines in preclinical engineered cancer models?
复制标题
DOI：
10.1242/dmm.049520
复制
发表时间：
2022-05-01
影响因子：
4.3
通讯作者：
中科院分区：
文献类型：
--
作者：
各种因素导致癌症风险和治疗结果的显著和可怕的差异。为了解决这个问题，有人呼吁将性别作为一个生物学变量，这导致更多的情况下，谨慎地将性别纳入癌症的临床前研究。癌症治疗中的另一个变量是遗传祖先。虽然这在临床研究中被明确考虑，但在临床前研究中却被大大忽视。临床前研究可以使用几种3D体外模型系统，例如球状体/类器官、异种移植物或结合联合收割机生物材料和细胞材料的其他生物工程系统。最终，所有这些体外模型系统的细胞基础都来自人类细胞系或患者样本，以研究癌症的机制并筛选新的治疗方法，所有这些都旨在最大限度地提高临床试验的成功率。这本身就提供了一个机会，可以增强对许多人群的有效治疗，当有意识地将遗传祖先等不同变量纳入研究设计时。这一观点强调了在临床前癌症组织工程中有意识地纳入遗传祖先的必要性，特别是当它涉及到确定治疗结果时。摘要：遗传决定因素，如血统，影响癌症风险和治疗结果。因此，这是一个重要的变量，考虑在生物医学研究的最初阶段在板凳上。
Diverse factors contribute to significant and dire disparities in cancer risk and treatment outcomes. To address this, there was a call for inclusion of sex as a biological variable, which resulted in more instances of careful inclusion of sex in preclinical studies of cancer. Another variable in cancer treatment is genetic ancestry. Although this is considered explicitly in clinical research, it is considerably neglected in preclinical studies. Preclinical research can use several 3D in vitro model systems, such as spheroids/organoids, xenografts, or other bioengineered systems that combine biomaterials and cellular material. Ultimately, the cellular base for all of these in vitro model systems is derived from human cell lines or patient samples, to investigate mechanisms of cancer and screen novel therapeutics, all of which aim to maximize successful outcomes in clinical trials. This in itself offers an opportunity to potentiate effective treatments for many groups of people, when diverse variables like genetic ancestry are consciously included into study design. This Perspective highlights the need for conscious inclusion of genetic ancestry in preclinical cancer tissue engineering, especially when it pertains to determining therapeutic outcomes. Summary: Genetic determinants, like ancestry, impact cancer risk and therapeutic outcomes. Hence, this is an important variable to consider at the very initial stages of biomedical research at the bench.
登录
查看更多内容
影响因子：
50.3
作者：
Carrot-Zhang, Jian;Chambwe, Nyasha;Beroukhim, Rameen
通讯作者：
Beroukhim, Rameen
影响因子：
64.5
作者：
Basu A;Bodycombe NE;Cheah JH;Price EV;Liu K;Schaefer GI;Ebright RY;Stewart ML;Ito D;Wang S;Bracha AL;Liefeld T;Wawer M;Gilbert JC;Wilson AJ;Stransky N;Kryukov GV;Dancik V;Barretina J;Garraway LA;Hon CS;Munoz B;Bittker JA;Stockwell BR;Khabele D;Stern AM;Clemons PA;Shamji AF;Schreiber SL
通讯作者：
Schreiber SL
影响因子：
5.7
作者：
Cattin S;Ramont L;Rüegg C
通讯作者：
Rüegg C
影响因子：
2.8
作者：
Baranyi, Marcell;Rittler, Dominika;Garay, Tamas
通讯作者：
Garay, Tamas
影响因子：
6.1
作者：
Hachey SJ;Movsesyan S;Nguyen QH;Burton-Sojo G;Tankazyan A;Wu J;Hoang T;Zhao D;Wang S;Hatch MM;Celaya E;Gomez S;Chen GT;Davis RT;Nee K;Pervolarakis N;Lawson DA;Kessenbrock K;Lee AP;Lowengrub J;Waterman ML;Hughes CCW
通讯作者：
Hughes CCW